Inzucchi SE, Docherty KF, Køber L, et al. - In the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial, the risk of cardiovascular mortality and worsening heart failure was reduced in correlation with administering the sodium–glucose cotransporter 2 inhibitor dapagliflozin, so researchers here examined how dapagliflozin affected incident type 2 diabetes (T2D) in the cohort enrolled in the trial that did not have diabetes. Randomization was performed of a subgroup of 2,605 patients with heart failure and reduced ejection fraction (HFrEF), no previous history of diabetes, and an HbA1c of < 6.5% at baseline to receive dapagliflozin 10 mg daily or placebo. Diabetes developed in 93 of 1,307 patients (7.1%) in the placebo group and 64 of 1,298 (4.9%) in the dapagliflozin group over a median follow-up of 18 months. Overall findings from this exploratory analysis suggest treatment with dapagliflozin to be correlated with reduced incidence of new diabetes among patients with HFrEF. A 32% reduction in diabetes incidence was seen after treatment with dapagliflozin.